Mirum Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mirum Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Mirum Pharmaceuticals Inc recorded a cumulative net loss of $-860 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -87.88%.

However, within the Healthcare sector 727 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 3300 to 4256.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	42.97 %	29.93 %	80.66 %	18.07 %	11.8 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-860	-799	-23	-41	-59
Return On Assets (TTM)	-87.88 %	-88.73 %	-2.75 %	-5.79 %	-8.55 %
MIRM's Total Ranking	# 4256	# 3300	# 3075	# 3222	# 3372
Total Assets (TTM) in million	1,045	891	1,200	779	731
Seq. Total Assets Change	17.29 %	-25.76 %	54.01 %	6.61 %	6.59 %
Seq. Net Income Change	-	-	-	-	-

MIRM's 5 Years Annual ROA >> Back to MIRM Management Effectiveness >> Compare MIRM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 336
Sector	# 728
Overall	# 4205

Return On Assets Statistics
High	Average	Low
-3.07 %	-34.2 %	-98.48 %
(Dec 31 2025)		(Mar 31 2026)

Financial Statements
Mirum Pharmaceuticals Inc 's Assets	$ 1,045 million	MIRM's Balance sheet
Mirum Pharmaceuticals Inc 's Income	$ -67 million	Quarterly MIRM's Income Statement
MIRM's Income by Division		See MIRM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	28.1 %	2.73 %	83.23 %	19.77 %	22.95 %
Total Assets in million	851	664	647	353	295
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-23	-88	-163	-136	-84
Annual Return On Assets	-2.75 %	-13.24 %	-25.27 %	-38.44 %	-28.5 %

MIRM's 5 Years Annual ROA >> Back to MIRM Management Effectiveness >> Compare MIRM ROA to its Competitors

More Return On Assets Ratios
MIRM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MIRM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MIRM's Competitors
Subscribers only: Roa for Mirum Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for MIRM's Customers

You may also want to know
MIRM's Roi	MIRM's Inventory Turnover Ratio	MIRM's Growth Rates	MIRM's Dividend Comparisons
	MIRM's Profitability Ratios	MIRM's Asset Turnover Ratio	MIRM's Dividend Growth
MIRM's Roe	MIRM's Valuation Ratios	MIRM's Financial Strength Ratios	MIRM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.